Utilization management, and the prior authorization decisions at the center of it, carries real cost implications for a health plan. Managing medical expenses responsibly is a legitimate part of running one. The question worth raising is what happens when cost becomes the primary lens a UM program is measured by, rather than one consideration among several. Turnaround time and administrative cost per case are measurable in a way that clinical accuracy often isn't, which makes them tempting as the default yardstick even when they aren't the right one.
That's the reframe we'd argue for here: not that cost doesn't matter, but that it isn't the target to aim at directly.
How Utilization Management Gets Framed Today
Throughput metrics, requests processed, average turnaround, and administrative cost per case are easy to measure and easy to put on a dashboard. Clinical accuracy is harder to quantify in the same way: it shows up unevenly, in appeal outcomes, provider escalations, and cases that had to be revisited, rather than in a single clean number. That difference in measurability is worth naming on its own, because it's a real reason cost and speed metrics tend to dominate program reporting even when they aren't the thing that actually matters most about a UM decision.
What Does a Clinical Lens for Utilization Management Look Like?
A clinical lens means measuring a UM program by the accuracy and speed of its decisions, not primarily by how cheaply or quickly it processes volume. In practice, that means asking whether a determination reflects the right clinical judgment given the evidence, and whether the member and provider got that answer quickly enough to matter, as the starting questions, rather than starting from what it cost to produce.
Federal policy is a useful reference point here, not because it settles the argument, but because it shows what the regulator has chosen to require. CMS-0057-F, in effect since January 2026, sets specific decision timeframes for prior authorization requests: 72 hours for urgent ones, 7 days for standard ones, and mandates that every denial include a specific, documented reason rather than a generic one. CMS-0062-P, a proposed rule released in April 2026 that would extend similar prior authorization requirements to drugs, is still working through the federal rulemaking process, with the comment period closed and a final rule expected later this year. What both rules actually require is speed within a defined window and a documented, specific rationale for any denial. Neither rule requires a cost target or a cost-efficiency metric. That's a fact about what's in the text, not a claim about what CMS intended or believes.
There's a reasonable argument that a program built this way costs less too, not because cost was the target, but as a byproduct: a determination made accurately the first time doesn't need to be revisited. We're not aware of a study that measures this directly for utilization management specifically, so we'd frame it as a logical inference rather than a documented result, but it's worth naming plainly rather than leaving it as an assumption we didn't call out.
Where Automation Helps in Utilization Management, and Where It Doesn't
Automation has a real, well-defined role in UM, and it's worth being specific about where that role starts and stops, and where human-in-the-loop review needs to take over.
Automation is well suited to intake: pulling structured data from a prior authorization request, verifying eligibility and benefits, gathering the clinical documentation a reviewer will need before they open the case. It's also well suited to applying explicit, well-defined criteria to genuinely clear-cut requests, the kind where the clinical guideline and the submitted evidence line up cleanly and there's no real judgment call to make. And it's useful for organizing everything a clinical reviewer needs into one place, so the reviewer starts from a complete picture instead of a blank chart.
What automation isn't suited for is the actual judgment call in an ambiguous or borderline case. That's not a limitation to work around. It's the correct division of labor. Clinical judgment exists to handle exactly the cases where the evidence doesn't cleanly resolve into an obvious answer, and that's precisely the kind of decision that should stay with a clinician, not get automated toward.
Why Human-in-the-Loop Design Matters for UM
The design principle that follows from this is straightforward, and it's the core of what human-in-the-loop actually means in practice: automate the parts of the workflow that are genuinely mechanical, and route everything that requires judgment to a person, with everything that person needs to make a good decision already assembled for them.
Concretely, that looks like a system that can move a prior authorization request straight to approval when it clearly and fully meets criteria, and sends every other case- anything ambiguous, incomplete, or borderline- to a clinical reviewer, along with the relevant guideline, the supporting evidence, and a clear reasoning trail showing how the case was evaluated. The reviewer isn't starting from scratch or hunting for context. They're making the actual judgment call the case requires, with everything they need in front of them. That handoff, not any single algorithm, is what human-in-the-loop design is actually protecting.
That same reasoning trail does double duty later. If a determination is appealed, whichever direction it went, there's already a documented record of what evidence was reviewed and how it was weighed against the guideline, rather than a reviewer having to reconstruct the logic from memory weeks or months after the fact. Defensibility built in at the point of decision is a different thing than defensibility assembled after someone asks for it.
What Changes for Medical Directors
For a medical director or VP of UM clinical operations, this reframe changes what the job is actually about. Instead of managing a queue and defending turnaround averages, the work becomes making sure the program is set up so clinical judgment lands where it's needed and nowhere else, and that every decision, whichever way it goes, is documented well enough to hold up under review or appeal without extra work after the fact.
That's a different kind of oversight than managing throughput. It means spending less time on the mechanics of moving requests through a queue and more time on the actual clinical question a UM program exists to answer: is this the right care, at the right time, based on the evidence in front of us? That's a better use of a medical director's expertise, and it's a more defensible program besides.
Galaxy UM is built around that division of labor. Clear-cut requests move to approval on their own; everything else lands on a clinical reviewer's desk already assembled, guideline, evidence, and reasoning trail included. What changes for a medical director isn't the mechanism itself; it's what they get to spend their time on once the mechanism is handling the part that doesn't need them.
Curious how Galaxy UM keeps clinical judgment at the center of every determination? Request a demo to see how the reasoning trail and review workflow come together.
A Few Common Questions
What does "auto-approve, never auto-deny" mean in utilization management?
It means a system can move a prior authorization request straight to approval when it clearly meets defined medical necessity criteria, but every other outcome- anything ambiguous, incomplete, or not clearly meeting criteria- is routed to a licensed clinical reviewer for a final decision rather than resolved automatically.
What does human-in-the-loop mean in utilization management?
Human-in-the-loop means a licensed clinician makes the final call on any prior authorization request that isn't a clear-cut match to defined criteria, with the supporting evidence, guideline, and reasoning trail already assembled for them. Automation supports the review. It doesn't replace the judgment.
What is CMS-0062-P?
CMS-0062-P is a proposed rule, released in April 2026, that would extend electronic prior authorization and decision-timeframe requirements to drugs, building on the CMS-0057-F final rule that covered non-drug items and services. It is still in the federal rulemaking process, with a final rule expected later in 2026.
How does clinical guideline automation work in utilization management?
Clinical guideline automation applies a plan's specific medical necessity criteria to a submitted request and surfaces a recommendation along with a documented reasoning trail. For clear-cut cases that fully meet criteria, that recommendation can move directly to approval. For everything else, it goes to a clinical reviewer along with the supporting evidence and guideline reference already assembled.
Does a clinical focus in utilization management still support cost management?
There's a reasonable case for it: a determination made accurately the first time doesn't need to be revisited, appealed, or reworked, and each of those carries its own cost. We're framing that as a logical argument rather than a measured result, since we don't have a study isolating that effect for utilization management specifically. The distinction that matters is that cost, if it improves, would be a result of clinical accuracy and speed, not the metric a program is designed around directly.